Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Otte took on the title in February, the culmination of nearly 25 years spent with the Danish drugmaker. As of his departure ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...

Novo Nordisk (NVO) said Wednesday it will cut costs as it faces increasing competition from Eli Lilly (LLY) and generic versions of its obesity drug Wegovy, with slower growth expected for its ...

Novo Nordisk data on obesity candidate CagriSema falls short of expectations, wiping around $94 billion off its market valuation.

Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials. The Danish pharma said that the Phase II trial of coramitug (PRX004), an mAb ...

Novo Nordisk is planning to open an artificial intelligence (AI) research facility in London, UK, as part of a drive to place the technology at the heart of its drug discovery operations. The ...

Read about Novo Nordisk AS ADR (NVO:XNYS) stock and today's latest news and financial updates.

Review the current Novo Nordisk AS ADR (NVO:XNYS) dividend yield and history to decide if NVO is the best investment for you.